PSD psivida limited

Analyst research article from (HUNTING PARTY SECURITIES,...

  1. jk7
    47 Posts.
    Analyst research article from (HUNTING PARTY SECURITIES, LTD.)
    pSivida Research Report - October 2004

    Page 3
    Recent Developments

    2004 is likely to be the breakthrough year for pSivida following the important
    developments of the past few months, which have confirmed the promise alluded to in
    our February 2004 research report. Since that time, pSivida has successfully completed
    the acquisition of 100% of its UK subsidiary pSiMedica, (previously 46% owned).



    Moreover, further patents with regard to the potential uses of BioSilicon™ have been
    granted and, most importantly Phase IIa human clinical trials commenced in June 2004
    with interim results due to be reported at the end of October 2004. Related to this, in
    September 2003, the Company announced extremely encouraging results from Singapore
    based subsidiary pSiOncology that successfully showed that its lead product 32-P -
    BioSilicon™ was successful in efficacy trials on animal models bearing human tumors.
    These first human trials are pivotal to the future development and perception of pSivida.



    If these results on tumor regression are replicated in man coupled with satisfactory safety
    data, we expect major pharmaceutical companies to seek to establish strategic
    partnerships with pSivida for its BioSilicon™ technology platform, making a significant
    rerating of the share price a strong likelihood.



    Todays announcement:
    Phase IIA BioSiliconTM trial in Man shows Safety and Tumor Regression...
 
watchlist Created with Sketch. Add PSD (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.